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Abstract. Background: There is limited information on pregnancy loss in women with HIV, and 
it is still debated whether HIV-related markers may play a role. 
Objectives: To explore potential risk factors for pregnancy loss in women with HIV, with 
particular reference to modifiable risk factors and markers of HIV disease. 
Methods: Multicenter observational study of HIV-positive pregnant women. The main outcome 
measure was pregnancy loss, including both miscarriage (<22 weeks) and stillbirth (≥22 weeks). 
Possible associations of pregnancy loss were evaluated in univariate and multivariate analyses.  
Results: Among 2696 eligible pregnancies reported between 2001 and 2018, 226 (8.4%) ended in 
pregnancy loss (miscarriage 198, 7.3%; stillbirth 28, 1.0%). In multivariate analyses, only older 
age (adjusted odds ratio [AOR] per additional year of age: 1.079, 95% confidence interval [CI] 
1.046-1.113), HIV diagnosis before pregnancy (AOR: 2.533, 95%CI 1.407-4.561) and history of 
pregnancy loss (AOR: 1.625, 95%CI 1.178-2.243) were significantly associated with pregnancy 
loss. No significant association with pregnancy loss was found for parity, coinfections, sexually 
transmitted diseases, hypertension, smoking, alcohol and substance use, CD4 cell count, HIV-
RNA viral load, and CDC HIV stage. 
Conclusions: Older women and those with a previous history of pregnancy loss should be 
considered at higher risk of pregnancy loss. The severity of HIV disease and potentially 
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Introduction. HIV infection, when appropriately 
treated, has currently a much less severe impact on the 
quality of life and life expectancy. This more favorable 
prognosis, together with the possibility to have healthy 
and uninfected children, has determined among women 
with HIV an increased desire for pregnancy, a more 
confident family planning, and increasing use of 
fertility treatments and services.1-8 In this context, 
miscarriage and stillbirth represent severe events that 
may have adverse consequences on parenting desire 
and family planning. It is therefore important to define 
determinants of pregnancy loss, identify pregnancies at 
risk, and implement targeted preventive measures that 
may increase the probability of delivering live and 
healthy newborns in this particular population. Large 
multinational projects,9 systematic reviews,10 and 
smaller regional studies11-13 have identified risk factors 
in the general population, but data in HIV-infected 
women are still sparse and often inconsistent, 
particularly with respect to the potential predictive role 
of some HIV-specific markers such as viral load and 
CD4+ cell levels.14-18 In order to further explore this 
issue, we used data from a national study to define 
determinants of pregnancy loss in a large cohort of 
pregnant women with HIV.  
 
Methods. We studied all miscarriages and stillbirths 
reported to the National Program on Surveillance on 
Antiretroviral Treatment in Pregnancy. This is a 
national observational study of pregnant women with 
HIV established in Italy in 2001.19 The study (currently 
not funded) was supported in the past by public, peer-
reviewed research grants (ref.: H85E08000200005) 
from the Italian Medicines Agency (AIFA), with no 
role of the funder in study design, data collection, data 
analysis, manuscript preparation and/or publication 
decision. The study is structured as a prospective 
cohort, with reporting recommended before pregnancy 
outcome. Retrospective reports are also allowed but 
represent roughly 20% of total cases in the project. 
Laboratory and clinical data are collected from hospital 
records of Obstetrics, Infectious Diseases and 
Paediatrics departments following women’s consent. 
Both the study protocol and patient information sheet 
were approved by the competent Ethics Committee 
(National Institute for Infectious Diseases L. 
Spallanzani, Rome). Information on past and recent 
(less than one year) substance use and on the HIV 
status of the current partner is based on the women’s 
reports. Status and level of smoking (with no smoking 
defined by less than one cigarette per day [CPD], light 
smoking by one to nine CPD and moderate to heavy 
smoking by 10 or more CPD)20 are defined at first visit 
in pregnancy.  Hypertension, diabetes, and alcohol 
consumption were defined according to national 
guidelines for the management of pregnancy.21 
Gestational age is determined on the basis of the last 
menstrual period, ultrasound biometry, or both. 
Preterm and very preterm delivery are defined as 
delivery before 37 and 32 completed weeks of 
gestation, respectively, and low and very low birth 
weight by values below 2500 and 1500 g, respectively. 
Cesarean section is considered elective if performed 
before the rupture of membranes and the onset of labor, 
and nonelective if performed after the rupture of 
membranes, the onset of labor, or both.   
For the present analysis we considered all the 
centres who reported at least one case of pregnancy 
loss (miscarriage, before 22 weeks of gestation; 
stillbirth, at or after 22 weeks) from December 2001 
(study start) to October 2018, and compared the 
pregnancies ending in a pregnancy loss with all the 
pregnancies with a live birth concurrently reported 
from the same centres. Voluntary terminations and 
cases with a diagnosis of HIV during the third trimester 
of pregnancy were excluded. The study period (2001-
2018) was divided into three intervals of six years each 
(2001-2006, 2007-2012, 2013-2018). The possible role 
of HIV-related variables was evaluated considering 
periconception values of CD4 cell count and plasma 
HIV-RNA as potential predictors of pregnancy loss. 
We considered for this analysis as periconception 
values all available CD4 cell counts and HIV-RNA 
values with a time distance no greater than 13 weeks 
before or after the date of the last menstrual period. 
HIV-RNA was categorized at a threshold of 50 copies 
per ml and CD4 cell levels at two different thresholds, 
of 200 cells/mm3 and 500 cells/mm3, respectively. 
Quantitative variables were summarized as medians 
with interquartile ranges (IQR) and compared using the 
Mann-Whitney U-test. Categorical variables were 
compared using the chi-square test, with odds ratios 
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(OR) and 95% confidence intervals (CI) calculated. 
Temporal trends were analyzed using the chi-square 
test for trend. In order to adjust for potential 
confounders, pregnancy loss was also evaluated as a 
dependent variable in multivariable logistic regression 
analyses, and sensitivity analyses were conducted 
individually valuating miscarriage and stillbirth as 
dependent variables and introducing other possibly 
relevant covariates as independent variables. P values 
below 0.05 were considered statistically significant. All 
analyses were performed using the SPSS software, 
version 25.0 (IBM Corp, 2017, Armonk, NY, USA). 
 
Results. As of October 2018, 2696/4132 pregnancies 
in the study database (65.2%) were eligible for analysis. 
Among those pregnancies, 226 (8.4%) ended in either 
miscarriage (198, 7.3%) or stillbirth (28, 1.0%). The 
rate of pregnancy loss remained substantially 
unchanged across the study period (7.4% in 2001-2006, 
10.3% in 2007-2012, 6.8% in 2013-2018; p=0.772, chi-
square for trend). No temporal trends were observed 
also analyzing separately miscarriage and stillbirth 
(data not shown).  
The general characteristics of the population studied 
according to pregnancy loss are shown in Table 1. The 
main markers of HIV disease, represented by CD4 cell 
count, HIV-RNA viral load, and CDC HIV stage, 
showed no differences between the two groups of 
women with and without pregnancy loss. Additional 
analyses conducted on CD4 levels categorized at 
different thresholds confirmed this finding: rates of 
pregnancy loss were 6.8% for CD4<200/mm3 and 8.2% 
for CD4 ≥200/mm3 (OR 0.822, 95%CI 0.436-1.550, 
p=0.545), 8.2% for CD4≥500/mm3 and 8.0% for CD4 
<500/mm3 (OR 1.018, 95% CI 0.740-1.400, p=0.912). 
 Women with pregnancy loss were significantly 
older, HIV-infected from a longer time, more 
frequently diagnosed with HIV and on antiretroviral 
treatment before pregnancy, had received more 
frequently preconception counseling, and were more
 
Table 1. Population characteristics at entry in pregnancy in women with and without pregnancy loss. 
Characteristic  
% (N) or median (IQR) 
OR, 95%CI P value # 
All Pregnancy loss No pregnancy loss 
Age (years) (n: 2695) 33 (29-36) 35 (31-39) 32 (28-36) n.a. <0.001 
Body mass index (Kg/m2) (n: 1968) 22.3 (20.2-25.3) 22.2 (20.3-24.5) 22.3 (20.1-25.3) n.a. 0.690 
Months from HIV diagnosis (n: 2595) 56 (12-116) 75 (33-136) 55 (10-114) n.a. <0.001 
CD4 cell count at entry in pregnancy (cells/mm3)  
(n: 2054) 476.5 (340-665) 474.5 (350-650) 476.5 (340-666.5) n.a. 0.885 
HIV already diagnosed before pregnancy (n: 2595) 79.1 (2052/2595) 92.2 (202/219) 77.9 (1850/2376) 3.378 (2.040-5.594) <0.001 
Preconception counselling § (n: 2332) 36.1 (843/2332) 49.8 (101/203) 34.9 (742/2129) 1.851 (1.386-2.472) <0.001 
African provenance (n: 2644) 35.0 (926/2644) 33.6 (74/220) 35.1 (852/2424) 0.935 (0.698-1.252) 0.653 
History of intravenous drug use (n: 2628) 9.4 (247/2628) 6.3 (14/224) 9.7 (233/2404) 0.621 (0.356-1.085) 0.091 
Partner without HIV infection (serodiscordant couple)  
(n: 1906) 63.5 (1210/1906) 65.5 (110/168) 63.3 (1100/1738) 1.100 (0.789-1.534) 0.574 
HIV symptomatic disease (CDC disease stage B or C)  
(n: 2615) 11.4 (297/2615) 12.9 (29/224) 11.2 (268/2391) 1.178 (0.782-1.776) 0.433 
HIV-RNA <50 copies/ml at conception (n: 1140) 53.4 (864/1933) 58.9 (66/112) 52.8 (543/1028) 1.282 (0.863-1.904) 0.219 
Antiretroviral-naïve (n: 2618) 31.4 (822/2618) 21.4 (48/224) 32.3 (774/2394) 0.571 (0.410-0.794) 0.001 
On antiretroviral treatment at conception (n: 2620) 55.7 (1459/2620) 67.1 (151/224) 54.6 (1308/2396) 1.721 (1.286-2.301) <0.001 
HBV-coinfected (n: 2504) 11.2 (280/2504) 7.1 (14/197) 11.5 (266/2307) 0.587 (0.336-1.026) 0.059 
HCV-coinfected (n: 1861) 20.2 (376/1801) 16.6 (27/163) 20.6 (349/1698) 0.767 (0.499-1.179) 0.226 
Hypertension (n: 2623) 2.2 (59/2623) 3.2 (7/221) 2.2 (52/2402) 1.478 (0.663-3.295) 0.339 
History of sexually transmitted diseases * (n: 2472) 18.8 (464/2472) 19.1 (40/209) 18.7 (424/2263) 1.027 (0.716-1.472) 0.887 
Recent substance use (n: 2540) 5.7 (144/2540) 2.9 (6/209) 5.9 (138/2331) 0.470  (0.205-1.077) 0.068 
Alcohol abuse  (n: 2266) 1.2 (27/2226) 0 (0/188) 1.3 (27/2078) n.a. 0.116 
Primiparous  (n: 2618) 25.2 (659/2618) 22.6 (50/221) 25.4 (609/2397) 0.858 (0.618-1.192) 0.362 
Twin pregnancy (n: 2679) 1.8 (48/2679) 1.9 (4/209) 1.8 (44/2470) 0.930 (0.331-2.613) 0.890 
History of pregnancy loss (n: 2559) 22.3 (571/2559) 32.1 (70/218) 21.4 (501/2341) 1.737 (1.286-2.347) <0.001 
Smoking, any (n: 2445) 25.3 (619/2445) 26.1 (52/199) 25.2 (567/2246) 1.047 (0.753-1.457) 0.783 
Smoking, heavy (10 or more cigarettes per day)  
(n: 2445) 12.2 (298/2445) 12.6 (25/199) 12.2 (273/2246) 1.038 (0.670-1.609) 0.866 
IQR: interquartile range; OR: odds ratio; CI: confidence interval; N.A.: not applicable.  
# Chi-square test or Mann-Whitney U test. *Chlamydia, Gonorrhea, Genital condylomatosis, Genital herpes, Syphilis, Trichomonas. § 
defined as preconception advice on health issues regarding pregnancy and HIV.   
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Table 2. Multivariable analysis of possible determinants of pregnancy loss. 
 Adjusted odds ratio (AOR) 95% CI p value 
Age (adjusted odds ratio per each additional year of age) 1.079 1.046-1.113 <0.001 
On antiretroviral treatment at conception 0.971 0.680-1.386 0.871 
Diagnosis of HIV before pregnancy 2.533 1.407-4.561 0.002 
African provenance 1.238 0.898-1.705 0.192 
Multiple (twin) pregnancy 0.524 0.124-2.204 0.378 
History of pregnancy loss 1.625 1.178-2.243 0.003 
 
likely to have experienced previous pregnancy losses. 
No differences were observed between the two groups 
in other possible risk factors for pregnancy loss, such 
as parity, coinfections, sexually transmitted diseases, 
hypertension, smoking, alcohol, and substance use.  
The above analyses were also conducted separately 
for miscarriage and stillbirth. For miscarriage, the 
results substantially overlapped those of the common 
analysis (data not shown). For stillbirth, the results 
showed significant associations with African 
nationality (odds ratio [OR]: 2.728, 95%CI 1.261-
5.904, p=0.011) and with twin pregnancy (OR: 4.356, 
95%CI 1.004-18.898, p=0.049). 
The associations found in the above univariate 
analyses were evaluated in a multivariable logistic 
regression analysis that included as dependent variable 
(outcome) pregnancy loss, and as independent 
(predictive) variables age, African provenance, HIV 
diagnosis before conception, being on antiretroviral 
treatment (ART) at conception, twin pregnancy, and 
history of pregnancy loss. Other variables significantly 
associated in univariate analyses with pregnancy loss 
were excluded being considered either redundant 
compared to others already included in the model 
(months since HIV diagnosis, antiretroviral status at 
entry in pregnancy) or reflecting spurious associations 
(preconception counseling, apparently increasing risk 
of pregnancy loss). The results of the multivariable 
analysis are shown in Table 2. After adjusting for 
covariates, only older age, the timing of HIV diagnosis 
and history of pregnancy loss remained significantly 
associated with pregnancy loss. Sensitivity analyses 
that included additional covariates in the model 
consistently confirmed the above results (data not 
shown).  
 
Discussion. This large study explored the determinants 
of pregnancy loss in a large series of roughly three 
thousand pregnancies with HIV. Our sample was 
entirely represented by HIV-positive women, and we 
were, therefore, unable to assess the role of HIV 
infection, that was reported as a significant risk factor 
in other studies.9 We were also unable to assess the role 
of other potentially relevant variables such as 
socioeconomic and marital status,9 placental and 
amniotic status.12 
As expected, most of the cases (198/226) of 
pregnancy loss were represented by miscarriages. The 
ratio between pregnancy loss and live birth remained 
relatively constant over time, with no significant 
change across the study period. In general, the 
observed rate (around seven percent of pregnancies) 
was lower compared to data reported for the general 
population in Italy (14% of all pregnancies in 2015),22 
and for pregnant women with HIV by others (15 and 
20% in the studies by Hoffman and Stringer, 
respectively),18,17 suggesting underreporting or missed 
enrolment of women with miscarriage in this 
surveillance. This occurrence might be favored by 
preferential access of women with early pregnancy loss 
to other structures, such as emergency departments. 
The observed rate of stillbirth (1.0%) is consistent with 
other studies, that usually showed rates between 0.8% 
and 4%.17,18,23 
The main objective of this study was to identify 
preventable determinants of pregnancy loss among 
women with HIV. In this large series, the two major 
determinants of pregnancy loss were represented by 
two non-modifiable risk factors, represented by older 
age and history of a previous pregnancy loss. Both 
these associations have already been described.9-12  
We found an association, apparently paradoxical, 
between pregnancy loss and preconception counseling. 
Our interpretation is that preconception counseling 
acted here as a proxy for the previous pregnancy losses 
or pregnancy at risk, with women with such a history 
more likely to seek preconception advise. The absence 
of a positive effect of preconception counseling in 
preventing pregnancy loss is nonetheless important, 
because is consistent with the absence of modifiable 
factors among the determinants found. Importantly, no 
significant role was found for smoking, alcohol, and 
recent substance use. This finding was confirmed in 
sensitivity analyses that included such variables in the 
main multivariable model (data not shown). We also 
found no effect of BMI, another potentially modifiable 
risk factor for pregnancy loss,10 also when the risk was 
assessed specifically for the presence of overweight 
and/or obesity (data not shown). Finally, we found no 
significant role of smoking, in discordance with the 
observations by Flenady et al in the general 
population10 and by Westreich et al in women with 
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HIV.16 We also found no association of pregnancy loss 
with hypertension and parity, that represented risk 
factors in larger studies evaluating the general 
population.9,10 In univariate analysis twin pregnancy 
represented a predictor of stillbirth, as reported by 
others.9 Although this association did not persist in the 
multivariable analysis, this lack of significance could 
be due to the limited number of stillbirth events, and 
we think that multiple pregnancy should be still 
considered as a potential risk factor for this adverse 
outcome. 
This study also contributed information to the 
debate on the potential role of severity of HIV disease 
in increasing the risk of pregnancy loss. We did not 
find any role for clinical or laboratory markers of HIV, 
confirming the findings by Stringer et al. for CD4 and 
HIV-RNA,17 but in discordance with the significant 
associations between pregnancy loss and HIV disease 
indicators (CD4, plasma HIV-RNA levels and clinical 
HIV stage) found in a previous study conducted in 
Zambia,4 while another study had found conflicting 
results, with a small absolute increase in risk of 
pregnancy loss for the highest viral load category 
compared to the lowest category, and a simultaneous 
paradoxical protective effect of increased cumulative 
viremia against pregnancy loss.15 Presence of ART at 
conception showed in the present series no association 
with pregnancy loss in multivariable analyses, 
confirming the findings of other studies and systematic 
reviews.17,18, 23,24  
The interpretation of the study should take into 
account some limitations. Study population may have 
been selected because of different reasons, that include 
missing outcome information (the main reason for 
patient ineligibility), exclusion of women diagnosed 
with HIV in late pregnancy (that might have higher 
viral load and lower CD4), and referral bias (with 
specialized centres more likely to participate in this 
surveillance).  The patient’s desire of acceptability may 
also have influenced the accurate reporting of personal 
risk factors/behaviors (e.g., smoking, substance use), 
and ascertainment of outcomes (particularly for 
miscarriage) is usually problematic. The low rate 
observed, actually, suggests incomplete coverage or 
underreporting of this outcome. Information on 
periconception HIV-RNA levels was also missing in a 
substantial number of cases, and this should prompt 
caution in the interpretation of the findings. Such a 
high rate of missing information, however, includes 
more than 500 cases in which HIV infection was 
diagnosed during pregnancy, and HIV-RNA analyzed 
for the first time at second or third trimester. This 
occurrence is also likely to have influenced through 
selection bias the finding of a higher risk of pregnancy 
loss in women diagnosed before current pregnancy, 
that should therefore also be considered cautiously.  
 
Conclusions. In conclusion, despite the above caveats, 
our findings show that pregnancy loss is a 
multifactorial outcome. Older women and those with a 
previous history of pregnancy loss should be 
considered at high risk of pregnancy loss, and twin 
pregnancy should be considered a risk factor for 
stillbirth. Our data indicated that modifiable factors, 
such as excess body weight, smoking, alcohol, and 
substance abuse, have a limited role in pregnancy loss. 
The degree of severity of HIV disease apparently did 
not increase the risk of pregnancy loss in general and 
of miscarriage in particular. Larger, possibly 
multinational studies may be necessary to define more 
accurately the determinants of stillbirth in women with 
HIV, given the low prevalence of this condition. 
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